Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa
Yoel Lubell, Arthorn Riewpaiboon, Arjen M Dondorp, Lorenz von Seidlein, Olugbenga A Mokuolu, Margaret Nansumba, Samwel Gesase, Alison Kent, George Mtove, Rasaq Olaosebikan, Wirichada Pan Ngum, Caterina I Fanello, Ilse Hendriksen, Nicholas PJ Day, Nicholas J White & Shunmay Yeung
Volume 89, Number 7, July 2011, 504-512
Table 5. Costa per disability-adjusted life year (DALY) averted and cost per death averted in each of the study sites
| Parameter | United Republic of Tanzania |
Mbarara, Uganda | Ilorin, Nigeria | All sites | |
|---|---|---|---|---|---|
| Muheza | Korogwe | ||||
| Mean incremental cost per patient treated with artesunate | 1.2 | −1.6 | 1.0 | 22.5 | 3.0 |
| Mean DALYs averted with artesunate | 0.7 (pooled data from all trial sites) | ||||
| NNTb to avert 1 death | 41 (pooled data from all trial sites) | ||||
| Cost/DALY averted | 1.5 | −2.0 | 1.2 | 28.1 | 3.8 |
| Cost/death averted | 49 | −66 | 41 | 922 | 123 |
NNT, number needed to treat.
a All costs in United States dollars.
b This represents the number of patients one would need to treat with artesunate instead of quinine to avert 1 death.